Pontchartrain Cancer Center

April 08, 2021

Kathy Oubre, MS, chief operating officer of Pontchartrain Cancer Center, discusses cost-saving implications of biosimilars in oncology, as well as several barriers that continue to impede their use.

April 01, 2021

Kathy Oubre, MS, chief operating officer, Pontchartrain Cancer Center, explores US adoption of biosimilars ahead of her panel discussion at the 2021 Community Oncology Conference, as well as what sessions she’s looking forward to attending.

September 25, 2020

More biosimilars are hitting the US market, but marketplace dynamics have made it difficult to take advantage of these therapies.

September 17, 2020

In the past 5 years, a community-based cancer clinic has undergone a large degree of change to achieve its goals of practice transformation and value-based care (VBC).

April 21, 2020

The clinicians and nurses at Pontchartrain Cancer Center address the education behind the clinical trials, which helps patients understand that they can have access to cutting edge therapy that they would not otherwise have access to, said Kathy W. Oubre, MS, chief operating officer at Pontchartrain Cancer Center. Kathy Oubre is additionally scheduled to speak at the Community Oncology Alliance Virtual Meeting, which runs from April 23-24, 2020.

April 10, 2020

Developing an expansive program to meet the needs of all of our patients, at all education levels, is 1 of the biggest challenges we face at Pontchartrain Cancer Center, said Kathy W. Oubre, MS, chief operating officer at Pontchartrain Cancer Center. Kathy Oubre is additionally scheduled to speak at the Community Oncology Alliance Virtual Meeting, which runs from April 23-24, 2020.